Drug
Nilotinib clinical trials
Also written Tasigna and AMN107.
- studies test it
- 136
- open now
- 8
- in phase 3
- 21
- first study started
- 2001
Keep track of what changes. Save the nilotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
136 studies that test it; most in 2009 (16)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 16 |
| 2010 | 16 |
| 2011 | 8 |
| 2012 | 10 |
| 2013 | 16 |
| 2014 | 8 |
| 2015 | 8 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 35
- Phase 2
- 70
- Phase 3
- 21
- Phase 4
- 16
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Leukemia
- 10
Who runs them
Industry 55 · Other 81
Novartis Pharmaceuticals (53) · Gruppo Italiano Malattie EMatologiche dell'Adulto (5) · National Cancer Institute (NCI) (4) · Georgetown University (4) · University Health Network, Toronto (3) · M.D. Anderson Cancer Center (3) · Mayo Clinic (2) · Medical College of Wisconsin (2)
Often tested with
Tested in the same studies.
Imatinib (20) · Dasatinib (10) · Paclitaxel (5) · Olaparib (4) · Ruxolitinib (4) · Durvalumab (3) · Palbociclib (3) · Pembrolizumab (2)
Studies
Open first, then newest update. How each study uses nilotinib is read from its arms, and is right about nine times in ten.
Testing it · 136
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelRecruitingPhase 2National Cancer Institute (NCI)NCT04449549Written as Nilotinib and Paclitaxel
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Nilotinib Hydrochloride Monohydrate
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingPhase 2Medical College of WisconsinNCT04838041Written as Nilotinib
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Nilotinib (400 mg BID)
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Nilotinib
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Nilotinib 100mg
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT06409936Written as Nilotinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Nilotinib
- Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT02379416Written as Nilotinib + Paclitaxel
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT03516279Written as Nilotinib
- Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01784068Written as Nilotinib followed by treatment-free
- Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)CompletedPhase 2Novartis PharmaceuticalsNCT01698905Written as nilotinib
- Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibCompletedPhase 4Novartis PharmaceuticalsNCT00756509Written as Nilotinib
- Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedPhase 2National Cancer Institute (NCI)NCT05185947Written as Nilotinib
- Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy BodiesCompletedPhase 2Georgetown UniversityNCT04002674Written as Nilotinib Oral Capsule
- Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)CompletedPhase 2University Hospital, BordeauxNCT01774630Written as Nilotinib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as Nilotinib
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell TumorCompletedPhase 2Andrew J. Wagner, MD, PhDNCT01207492Written as nilotinib
- Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedPhase 2University Hospital, LilleNCT02891395Written as Imatinib Mesylate and Nilotinib
- Nilotinib With Radiation for High Risk ChordomaCompletedPhase 1Massachusetts General HospitalNCT01407198Written as Nilotinib
See all 136 studies that test nilotinib →
Given in every arm · 12 — nilotinib is usual care beside what is tested
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNot yet recruitingPhase 2The University of Hong KongNCT07493408Written as Nilotinib
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT04835584Written as Nilotinib
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT02611492Written as Nilotinib
- Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingPhase 2University of JenaNCT03906292Written as Nilotinib 300 mg
- Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554341Written as Nilotinib Hydrochloride Monohydrate
- A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedPhase 2Novartis PharmaceuticalsNCT03874858Written as Nilotinib
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingPhase 2SWOG Cancer Research NetworkNCT03654768Written as Nilotinib
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML PatientsCompletedPhase 3Hospices Civils de LyonNCT02201459Written as Nilotinib (Tasigna ®), capsules of 150 mg
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedPhase 1M.D. Anderson Cancer CenterNCT01751425Written as Nilotinib
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedPhase 1Novartis PharmaceuticalsNCT02081378Written as Nilotinib
- Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownPhase 4Gruppo Italiano Malattie EMatologiche dell'AdultoNCT02602314Written as Nilotinib
- Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and SunitinibCompletedPhase 3Novartis PharmaceuticalsNCT00471328Written as Nilotinib
As the comparator · 9 — what is tested is compared with nilotinib
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07885293Written as Nilotinib
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Nilotinib
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05456191Written as Nilotinib
- Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseCompletedPhase 2Georgetown UniversityNCT02954978Written as Nilotinib 150mg oral capsule [Tasigna]
- Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedPhase 2Novartis PharmaceuticalsNCT03578367Written as Nilotinib
- TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER StudyCompletedPhase 3University of JenaNCT01657604Written as Nilotinib
- A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedPhase 3Ariad PharmaceuticalsNCT02627677Written as Nilotinib 400 mg BID
- An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two YearsTerminatedPhase 3Prof. Dr. Nikolas von BubnoffNCT02174445Written as Nilotinib
- Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedPhase 3Hamad Medical CorporationNCT03079505Written as Nilotinib 150mg oral capsule [Tasigna]
Codes
What other systems call nilotinib · ClinicalTrials.gg INT004754
- MeSH (NLM) C498826nilotinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F41401512XNILOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 662281Confirmed FDA, Wikidata
- Wikidata Q412327nilotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48375NilotinibOne source FDA
- DrugBank DB04868One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C498826 | nilotinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F41401512X | NILOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 662281 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412327 | nilotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48375 | Nilotinib | One source FDA |
| DrugBank | DB04868 | — | One source Wikidata |
Also registered as nilotinib dihydrochloride dihydrate (UNII WM15I3PF3G), nilotinib hydrochloride anhydrous (UNII K37N7BYX3X · RxNorm 1804015), nilotinib hydrochloride dihydrate (UNII Y37S7HA3BC) and nilotinib hydrochloride monohydrate (UNII 5JHU0N1R6K).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.